Overview

A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy

Status:
Recruiting

Trial end date:
2023-04-21

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to investigate the long-term safety and tolerability of TAK-935/OV935 as an adjunctive therapy in patients with rare epilepsies.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Collaborator:

Ovid Therapeutics